Continued Access to RXDX-105

Phase 1

Completed

• Conditions: RET Gene Mutation; Ovarian Cancer; BRAF Gene Mutation; Non Small Cell Lung Cancer
• Interventions: Drug: RXDX-105

• Registration Number: NCT03784378
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2018-12-14
• Study First Submitted: 2018-12-17
• Study First Submitted QC: 2018-12-18
• Study First Posted: 2018-12-21
• Status Verified: 2020-09
• Primary Completion: 2020-09-30
• Study Completion: 2020-09-30
• Last Update Submitted: 2020-09-30
• Last Update Posted: 2020-10-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

• This individual patient protocol includes treatment for 3 patients previously enrolled on IRB #15-270 (phase1/1b clinical trial RXDX-105-01):

Read More

Exclusion Criteria

• Any patients other than those described above are excluded.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Participants previously enrolled on Study of RXDX-105	RXDX-105	Participants were previously enrolled on Study of RXDX-105

Primary Outcome Measures

Name	Time	Method
Evaluation during treatment/intervention	Through study completion, up to five years.	Safety assessments will be performed as standard of care and as clinically indicated. This will include monitoring of adverse events, including serious adverse events including CTCAE grading.

Trial Locations

Locations (1)

Memorial Sloan Kettering Cancer Center 1275 York Avenue; 🇺🇸 New York, New York, United States